Actively Recruiting
Long-Term Study of Filgotinib for Safety and Effectiveness in Children and Teens Aged 8 to Under 18 with Juvenile Idiopathic Arthritis
Led by Alfasigma S.p.A. · Updated on 2026-08-10
80
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This study focuses on children and adolescents aged 8 to less than 18 years who have juvenile idiopathic arthritis JIA, specifically those with polyarticular or systemic forms of the disease. It aims to evaluate the long-term safety, tolerability, and effectiveness of filgotinib in patients who have already completed treatment in earlier parent studies and shown clinical benefit by controlling their disease symptoms, as judged by their doctors. Participants will receive filgotinib, an investigational drug given as film-coated tablets taken orally once daily in the morning, with or without food. The study is an open-label extension, meaning all participants will receive filgotinib. This phase 3 trial will last up to 78 weeks, during which participants continue treatment and are monitored for safety and response. Throughout the study, participants will attend regular visits where researchers will assess adverse events and measure disease activity using criteria such as the JIA American College of Rheumatology ACR response and remission rates. Safety monitoring includes tracking any serious side effects or infections. The total study duration extends up to 78 weeks, allowing for long-term observation of how participants tolerate and respond to filgotinib treatment.
CONDITIONS
Brief Title
OLE Study With Filgotinib in JIA
Research Team
C
Catherine Vincent
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here